February 23, 2021
vTv Therapeutics Announces Results from SimpliciT-1 Study of TTP399 in Patients with Type 1 Diabetes
Led by Klara Klein, MD, PhD, the study showed that treatment with 800mg of TTP399 demonstrated statistically significant reductions in HbA1c and clinically relevant reduction in the frequency of severe or symptomatic hypoglycemia.